Research Papers:
Deregulated FADD expression and phosphorylation in T-cell lymphoblastic lymphoma
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 2531 views | HTML 3642 views | ?
Abstract
José L. Marín-Rubio1,2,3, María C. de Arriba4,5, María A. Cobos-Fernández1,2, Laura González-Sánchez1,2,6, Inmaculada Ors3, Isabel Sastre1, José Fernández-Piqueras1,2,3,6, María Villa-Morales1,2,3,6
1Centro de Biología Molecular Severo Ochoa (CBMSO), Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid (CSIC-UAM), Madrid, Spain
2IIS-Fundación Jiménez Díaz, Madrid, Spain
3Universidad Autónoma de Madrid, Departamento de Biología, Madrid, Spain
4Universidad Carlos III, Departamento de Bioingeniería, Madrid, Spain
5Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain
6Centro de Investigaciones Biomédicas en Red de Enfermedades Raras (CIBERER), Valencia, Spain
Correspondence to:
María Villa-Morales, email: [email protected]
José Fernández-Piqueras, email: [email protected]
Keywords: T-cell lymphoblastic lymphoma, Fas-associated death domain protein (FADD), expression and phosphorylation, tumor aggressiveness, prognostic marker
Received: April 20, 2016 Accepted: August 11, 2016 Published: August 18, 2016
ABSTRACT
In the present work, we show that T-cell lymphoblastic lymphoma cells exhibit a reduction of FADD availability in the cytoplasm, which may contribute to impaired apoptosis. In addition, we observe a reduction of FADD phosphorylation that inversely correlates with the proliferation capacity and tumor aggressiveness. The resultant balance between FADD-dependent apoptotic and non-apoptotic abilities may define the outcome of the tumor. Thus, we propose that FADD expression and phosphorylation can be reliable biomarkers with prognostic value for T-LBL stratification.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 11370